HCPLive Network

Care Based on Intracranial Pressure Not Superior in Traumatic Brain Injury

 
WEDNESDAY, Dec. 12 (HealthDay News) -- For patients with severe traumatic brain injury (TBI) treated in the intensive care unit, treatment based on maintaining monitored intracranial pressure is not superior to care based on imaging and clinical examination, according to a study published online Dec. 12 in the New England Journal of Medicine.

Randall M. Chesnut, M.D., from the University of Washington in Seattle, and colleagues conducted a multicenter trial involving 324 patients aged 13 years or older with severe TBI. The participants were randomly allocated to receive guidelines-based management, in which a protocol for monitoring intraparenchymal intracranial pressure was used, or a treatment protocol based on imaging and clinical examination.

The researchers observed no significant difference between the groups in the primary outcome, a composite measure based on 21 assessments of functional and cognitive status, and six-month mortality was also not significantly different between the groups (P = 0.60). There was no significant difference in the median length of stay in the intensive care unit between the groups, although the imaging-clinical examination group had a higher number of days of brain-specific treatments (4.8 versus 3.4; P = 0.002). There was a similar distribution of serious adverse events between the groups.

"Our data suggest that a reassessment of the role of manipulating monitored intracranial pressure as part of multimodality monitoring and targeted treatment of severe traumatic brain injury is in order," the authors write.

The study was funded in part by Integra Life Sciences; all of the study authors disclosed financial ties to Integra Life Sciences as well as to two personal injury law firms.
 

Abstract
Full Text
Editorial

 
Copyright © 2012 HealthDay. All rights reserved.
 
 

Further Reading
Researchers at Hong Kong University and the Wellcome Trust Sanger Institute have identified a link between the influenza A viruses’ genetic diversity and severity of the infection.
Carol Burke, MD, FACG, FASGE, talks about her phase-3 placebo-controlled trial of Celecoxib in pediatric subjects with familial adenomatous polyposis (FAP) at the 2014 ACG Annual Meeting in Philadelphia, PA.
Carol Burke, MD, FACG, FASGE, discusses pediatric familial adenomatous polyposis (FAP) and colorectal cancer at the 2014 ACG Annual Scientific Meeting in Philadelphia, PA.
The immune system is the new focus of much work on traumatic brain injury (TBI). In a challenge to the paradigm that the blood brain barrier prevents harmful leukocytes from entering the brain, a Texas team tried to neutralize the impact of these cells. Peripheral lymphocytes are activated after TBI. They may then act as potential antigen presenting cells and get into the brain, causing cells there to degenerate.
Black women undergoing in vitro fertilization are only about half as likely as white women to become pregnant, and the racial disparity persists even when donor eggs are used. These findings are being presented at the annual meeting of the American Society for Reproductive Medicine, held from Oct. 18 to 22 in Honolulu.
Hospital conversion to for-profit status is associated with improvements in financial margins, but has no effect on process quality metrics or mortality rates, according to a study published in the Oct. 22/29 issue of the Journal of the American Medical Association
Drinking sugar-sweetened sodas may affect cellular aging by shortening telomere length, according to research published online Oct. 16 in the American Journal of Public Health.
More Reading